Rigel Pharma (RIGL) Misses Q4 EPS by 1c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Rigel Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
February 28, 2019 4:01 PM ESTSOUTH SAN FRANCISCO, Calif., Feb. 28, 2019 /PRNewswire/ --Â Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided a business update.
Recent Highlights
Fourth quarter 2018 total revenues were $37.9 million; including $30.6 million in collaboration revenues and $7.3 million in net product sales of TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment Full year 2018 total revenues were $44.5 million, including $13.9 million in net... More